Designing and Analyzing Clinical Trials for Personalized Medicine (DACTPerM)

In medical research, the treatment paradigm is shifting toward personalized medicine, where the goal is to match patients to the treatments most likely to deliver benefit. Treatment effects in various subpopulations may provide some information about treatment effects in other subpopulations. This working group will develop methodology and best practice guidelines for clinical trial design where treatments are being investigated or tested in several groups of patients. Key Deliverable: Working Group will produce and disseminate a white paper that will serve as guidelines for designing and analyzing clinical trials for personalized medicine and testing heterogeneity of treatment effects.

Leadership

Name (CTSA HUB)  Role 
Byron J Gajewski (Kansas) Co-Lead
Matthew S Mayo (Kansas) Co-Lead

Membership

Last Name First Name CTSA Hub
Bagiella Emilia Mount Sinai
Barohn Richard University of Kansas Medical Center
Berry Scott Berry Consultants/KUMC
Chen Zhengjia Emory
Dzomba Bari Penn State
Fontanesi John UCSD
Gajewski Byron University of Kansas Medical Center
Jennings Kristofer University of Texas Medical Branch
Karanevich Alex University of Kansas Medical Center
Lai Wei The Ohio State University
Long Qi Emory
Mayo Matthew University of Kansas Medical Center
Mermelstein Robin University of Illinois at Chicago
Messinger Shari Miami
 Pollock Brad University of California, Davis
Rickey Carter Mayo
Selker Harry Tufts
Tardiff Barbara Pfizer, Inc.
Torner Jim University of Iowa
Zend Donglin University of North Carolina at Chapel Hill

Meeting Schedule

4th Wednesday of each month, 2-3pm ET

Contact

methods_processes@ctsac4.org